Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

41.42USD
16 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$41.42
Open
--
Day's High
--
Day's Low
--
Volume
21
Avg. Vol
20,633,657
52-wk High
$41.64
52-wk Low
$32.32

Latest Key Developments (Source: Significant Developments)

Pfizer Inc, In July 2018, DOJ Requested Documents Related To Contracts With Iraqi Ministry Of Health, Which Co Will Be Providing
Thursday, 9 Aug 2018 04:44pm EDT 

Aug 9 (Reuters) - Pfizer Inc ::PFIZER INC - IN JULY 2018, DOJ REQUESTED DOCUMENTS RELATED TO CONTRACTS WITH IRAQI MINISTRY OF HEALTH, WHICH CO WILL BE PROVIDING.  Full Article

U.S. FDA Grants Priority Review For Pfizer's NDA For Glasdegib
Wednesday, 27 Jun 2018 08:00am EDT 

June 27 (Reuters) - Pfizer Inc ::U.S. FDA GRANTS PRIORITY REVIEW FOR PFIZER’S NEW DRUG APPLICATION FOR GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA.PFIZER INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR A DECISION BY FDA IS IN DECEMBER 2018.  Full Article

ACCC Seeks Special Leave To Appeal Full Federal Court's Pfizer Australia Pty Judgment
Monday, 25 Jun 2018 02:59am EDT 

June 25 (Reuters) - AUSTRALIAN COMPETITION & CONSUMER COMMISSION::SEEKS SPECIAL LEAVE TO APPEAL FULL FEDERAL COURT’S PFIZER AUSTRALIA PTY JUDGMENT.  Full Article

IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
Wednesday, 18 Apr 2018 06:12am EDT 

April 18 (Reuters) - Pfizer Inc ::INTERNATIONAL BROTHERHOOD OF TEAMSTERS - URGES PFIZER SHAREHOLDERS TO VOTE FOR PROPOSAL 7 FOR CORPORATE POLITICAL SPENDING DISCLOSURE.  Full Article

Pfizer Will Relocate Its Global Headquarters From 235 East 42nd Street To Spiral
Tuesday, 10 Apr 2018 08:30am EDT 

April 10 (Reuters) - Pfizer Inc ::PFIZER SIGNS LEASE FOR THE SPIRAL AT HUDSON YARDS IN MANHATTAN.CURRENTLY IN PROCESS OF SELLING ITS HEADQUARTERS PROPERTY ON EAST 42(ND) STREET.PFIZER INC - AS PART OF 20-YEAR LEASE AGREEMENT, PFIZER WILL RELOCATE ITS GLOBAL HEADQUARTERS FROM 235 EAST 42ND STREET TO SPIRAL.YEAR LEASE FOR SPIRAL, AN OFFICE TOWER BEING BUILT BY TISHMAN SPEYER, AT 66 HUDSON BOULEVARD AT HUDSON YARDS OF MANHATTAN.  Full Article

Pfizer and Allogene enter into agreement for Pfizer's CAR T cell therapy
Tuesday, 3 Apr 2018 08:00am EDT 

April 3 (Reuters) - Pfizer Inc ::SAYS CO AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-­ONCOLOGY PORTFOLIO.SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER'S CAR T CELL THERAPY.SAYS ALLOGENE WILL RECEIVE RIGHTS FROM CO TO 16 PRE-CLINICAL CAR T ASSETS LICENSED FROM CELLECTIS AND SERVIER.SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19.SAYS CO WILL HOLD 25 PERCENT STAKE IN ALLOGENE THERAPEUTICS; CO WILL BE REPRESENTED ON ALLOGENE'S BOARD.  Full Article

GSK did not put in final bid for Pfizer consumer unit - source
Friday, 23 Mar 2018 06:13am EDT 

March 23 (Reuters) - Glaxosmithkline Plc GSK.L::GLAXOSMITHKLINE DID NOT PUT IN A FINAL BID FOR PFIZER'S CONSUMER HEALTHCARE UNIT - SOURCE FAMILIAR WITH SITUATION.  Full Article

Pfizer says continues to evaluate options for consumer health
Friday, 23 Mar 2018 04:54am EDT 

March 23 (Reuters) - Pfizer Inc ::PFIZER SAYS CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR THE CONSUMER HEALTHCARE BUSINESS, INCLUDING A SPIN-OFF,SALE OR OTHER TRANSACTION, AND PFIZER ULTIMATELY RETAINING THE BUSINESS..PFIZER SAYS HAS NOT YET MADE A DECISION, BUT CONTINUES TO EXPECT ONE IN 2018.  Full Article

GlaxoSmithKline Withdraws From Process Relating To Pfizer's Consumer Healthcare Business​
Friday, 23 Mar 2018 03:44am EDT 

March 23 (Reuters) - Glaxosmithkline Plc ::‍CONFIRMS IT HAS WITHDRAWN FROM PROCESS RELATING TO PFIZER'S CONSUMER HEALTHCARE BUSINESS​.  Full Article

Pfizer Says Continues To Evaluate Potential Strategic Alternatives For Consumer Healthcare Business
Wednesday, 21 Mar 2018 05:41pm EDT 

March 21 (Reuters) - Pfizer Inc ::PFIZER - CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR CONSUMER HEALTHCARE BUSINESS.PFIZER - POTENTIAL ALTERNATIVES FOR CONSUMER HEALTHCARE BUSINESS,INCLUDE SPIN-OFF,SALE OR OTHER TRANSACTION,AND PFIZER ULTIMATELY RETAINING BUSINESS.  Full Article

Photo

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

FRANKFURT Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.